Sign in
Not yet recruitingNo phase

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
1,000 people, planned
Starts
1 Dec 2026
Expected to end
1 Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Plasma H3.1 concentration
  • NEWS2 score
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • All genders patients
  • Aged of 18 years or older
  • Proven or suspected infection
  • At least one risk factor for sepsis (cf HAS recommendations) :; Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery; Inborn immune deficit; Acquired immune deficit :; Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease); Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,; Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis
  • Informed consent

Who cannot take part

  • Previous enrolment
  • Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  • Refused to consent participating in the study,
  • Pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

Read full original descriptionShow less

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

The 2 groups in the trial

  • NEWS2 and H3.1-guided diagnostic and management strategyTreatment being tested

    Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol. Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below : * If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation. * If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required. * In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

    Treatment: Plasma H3.1 concentration and NEWS2 score

  • Usual careOther group

    Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

    Treatment: Plasma H3.1 concentration and NEWS2 score

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection
Record updated
17 November 2026